Search Results
May 27, 2026, 08:31 ET Wet AMD Market Set for Robust Growth Through 2036, Driven by Advancements in Anti-VEGF Therapies | DelveInsight
Therapeutics), ABI-110 (Avirmax Biopharma), and others.Adverum Biotechnologies' Ixoberogene soroparvovec (Ixo-vec, previously known as ADVM-022) is a clinical-stage gene therapy candidate from Adverum being developed for the treatment of wet age-related macular degeneration (wet AMD). It employs
More news about: DelveInsight Business Research, LLP
Dec 09, 2025, 08:28 ET Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition
INDIANAPOLIS, Dec. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Adverum Biotechnologies, Inc. (NASDAQ: ADVM) today announced that the tender offer (the "Offer") by Flying Tigers Acquisition Corporation ("Purchaser"), a direct wholly-owned subsidiary of Lilly,
More news about: Eli Lilly and Company
Nov 19, 2025, 18:18 ET Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights
multimedia:https://www.prnewswire.com/news-releases/halper-sadeh-llc-encourages-brns-fitb-advm-hban-shareholders-to-contact-the-firm-to-discuss-their-rights-302620950.html
More news about: Halper Sadeh LLP
Nov 19, 2025, 14:10 ET $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-HOUS, ADVM, HBAN, and COMP
ADVM ) related to its sale to Eli Lilly and Company. Under the terms of
More news about: Monteverde & Associates PC
Oct 27, 2025, 13:01 ET HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
multimedia:https://www.prnewswire.com/news-releases/halper-sadeh-llc-encourages-advm-plym-rna-shareholders-to-contact-the-firm-to-discuss-their-rights-302595545.html
More news about: Halper Sadeh LLP
Oct 24, 2025, 17:30 ET $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Adverum Biotechnologies, Inc. (NASDAQ: ADVM)
ADVM) related to its sale to Eli Lilly and Company. Under the terms of the proposed transaction, Adverum shareholders will receive $3.56 per share
More news about: Monteverde & Associates PC
Oct 24, 2025, 13:47 ET Shareholder Alert: The Ademi Firm investigates whether Adverum Biotechnologies, Inc. is obtaining a Fair Price for its Public Shareholders
MILWAUKEE, Oct. 24, 2025 /PRNewswire/ -- The Ademi Firm is investigating Adverum (Nasdaq: ADVM) for possible breaches of fiduciary duty and other violations of law in its transaction with Eli Lilly.
More news about: Ademi LLP
Oct 24, 2025, 08:30 ET Lilly to Acquire Adverum Biotechnologies
Calif., Oct. 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy with the aim of preserving sight for life in highly prevalent ocular diseases,
More news about: Eli Lilly and Company